Glucagon-Like Peptide-1 Agonist (GLP-1)

Phase 2Small molecule

Glucagon-Like Peptide-1 Agonist (GLP-1) is one of 46 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Alcohol Use DisorderNot yet recruiting

Type 2 Diabetes MellitusPreclinical

Active, not recruiting

Alcohol Use DisorderPhase 2

Not yet recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Tanzeum

GSK

Preclinical

10 2

NOVOLIN R

Novo Nordisk

Preclinical

1 3

Cipro

Myrbetriq

Golytely

Dostinex

Glucagon-Like Peptide-1 Agonist (GLP-1)

Johnson & Johnson

Phase 2

2 8

Lantus

Sanofi

Preclinical

6 9

Lixisenatide

Sanofi

Preclinical

4 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Alcohol Use Disorder

NCT07249554

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus2 trials

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03492580·714,582 enrolled

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03249506·25,358 enrolled

Alcohol Use Disorder1 trial

Preliminary Safety and Efficacy of Semaglutide and Naltrexone Combination Therapy for Alcohol Use Disorder

Not yet recruiting·JJohns Hopkins University·Phase 2·NCT07249554·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Glucagon-Like Peptide-1 Agonist (GLP-1). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glucagon-Like Peptide-1 Agonist (GLP-1) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glucagon-Like Peptide-1 Agonist (GLP-1). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

Glucagon-Like Peptide-1 Agonist (GLP-1)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Type 2 Diabetes Mellitus2 trials

Alcohol Use Disorder1 trial

References

Drug Info

Quick Facts

Related News